Selection of Systemic Therapies in Progressive DTC and the Role of Multidisciplinary Evaluation

In this segment, Dr. Greg Randolph discusses how and when systemic therapy is selected for patients with progressive differentiated thyroid cancer (DTC), emphasizing that these are nuanced, team-based decisions rather than simple algorithmic steps. As patients transition from surgery to endocrinology and then to medical oncology, each “handoff” represents both a vulnerability and an opportunity for coordinated care.

He underscores that medical oncologists typically lead management once metastatic disease is progressing, but optimal care requires continued involvement of surgeons and endocrinologists/endocrine oncologists. Key considerations include performance status, overall health (prehabilitation), rate and pattern of radiographic progression, radioactive iodine resistance, symptom burden, and the anatomical location of metastases (e.g., spine, mediastinum, pleura).

Dr. Randolph highlights a growing trend toward earlier initiation of systemic therapy, at the stage of clear radiographic progression but before overt symptoms, supported by the expanding arsenal of effective systemic agents and subsequent treatment options in advanced DTC.